IMCIL POWDER FOR SOLUTION FOR INJECTION OR INFUSION 500MG500MG PER VIAL

Nazione: Singapore

Lingua: inglese

Fonte: HSA (Health Sciences Authority)

Principio attivo:

Cilastatin sodium eqv cilastatin; Imipenem monohydrate eqv imipenem

Commercializzato da:

PHARMAKOE PTE. LTD.

Codice ATC:

J01DH51

Forma farmaceutica:

INJECTION, POWDER, FOR SOLUTION

Composizione:

Cilastatin sodium eqv cilastatin 500mg; Imipenem monohydrate eqv imipenem 500mg

Via di somministrazione:

INTRAVENOUS

Tipo di ricetta:

Prescription Only

Prodotto da:

ANFARM HELLAS S.A.

Stato dell'autorizzazione:

ACTIVE

Data dell'autorizzazione:

2021-07-21

Scheda tecnica

Company logo
IMCIL POWDER FOR SOLUTION FOR INJECTION OR INFUSION
500MG/500MG
(IMIPENEM AND CILASTATIN)
IMCIL (imipenem as monohydrate and cilastatin as sodium) is a broad
spectrum beta-lactam
antibiotic supplied as an intravenous infusion. IMCIL consists of two
components: (1)
imipenem, the first of a new class of beta-lactam antibiotics, the
thienamycins; and (2) cilastatin
sodium, a specific enzyme inhibitor that blocks the metabolism of
imipenem in the kidney, and
substantially increases the concentration of intact imipenem in the
urinary tract. Imipenem and
cilastatin sodium are present in IMCIL in a 1:1 ratio by weight.
The thienamycin class of antibiotics, to which imipenem belongs, is
characterized by a
spectrum of potent bactericidal activity broader than that provided by
any other antibiotic
studied.
MICROBIOLOGY
IMCIL is a potent inhibitor of bacterial cell-wall synthesis and is
bactericidal against a broad
spectrum of pathogens-gram-positive and gram-negative, aerobic and
anaerobic.
IMCIL shares with the newer cephalosporins and penicillins a broad
spectrum of activity
against gram-negative species, but is unique in retaining the high
potency against gram-positive
species, previously associated only with earlier narrow-spectrum
beta-lactam antibiotics. The
spectrum of activity of IMCIL includes Pseudomonas aeruginosa,
Staphylococcus aureus,
Enterococcus
faecalis
and
Bacteroides
fragilis,
a
diverse
group
of
problem
pathogens
commonly resistant to other antibiotics.
IMCIL is resistant to degradation by bacterial beta-lactamases, which
makes it active against a
high percentage of organisms such as Pseudomonas aeruginosa, Serratia
spp., and Enterobacter
spp., which are inherently resistant to most beta-lactam antibiotics.
The antibacterial spectrum of IMCIL is broader than that of any other
antibiotic studied, and
includes virtually all clinically significant pathogens. Organisms
against which IMCIL is
usually active in vitro include:
Gram-Negative Aerobes
Achromobacter spp.
Acinetobacter spp. (formerly Mi